CD8A and neoplasm: Since presenting tumour-derived antigens by APCs to tumour-specific CD8+ T-cells in the lymph nodes is a fundamental step to trigger a proper anti-tumour immune response, we evaluated whether Drd3-deficiency of tumour-specific CD8+ T-cells affected their migration through the secondary lymphoid organs.